OSLO, Norway--(BUSINESS WIRE)--Quarterly report - Q1 – 27 May 2015
Quarterly report – Q2 – 26 August 2015
Quarterly report – Q3 – 21 October 2015
Annual general meeting – 27 May 2015
About Nordic Nanovector ASA
Nordic Nanovector ASA is a privately held company established in 2009. The company is developing innovative radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other difficult to treat cancers. Nordic Nanovector intends to commercialise its product candidates through strategic alliances and partnerships with experienced oncology businesses and by establishing its own sales and marketing capabilities in selected markets. The company is based and has offices and laboratories in Oslo, Norway.
The company’s lead product candidate, Betalutin™, is a radioimmunotherapeutic that aims to prolong and improve the quality of life of people who suffer from NHL. Further information can be found at: www.nordicnanovector.com.
This information was brought to you by Cision http://news.cision.com